loading...| Preferred Name |
Elotuzumab |
|
| Synonyms |
|
|
| Definitions |
A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C66982 |
|
| Accepted_Therapeutic_Use_For |
multiple myeloma (MM) |
|
| ALT_DEFINITION |
A monoclonal antibody being studied in the treatment of advanced multiple myeloma. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. HuLuc63 binds to CS1, a protein that is found mainly on the surface of multiple myeloma cells. |
|
| CAS_Registry |
915296-00-3 |
|
| code |
C66982 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells. |
|
| Display_Name |
Elotuzumab |
|
| FDA_UNII_Code |
1351PE5UGS |
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Elotuzumab |
|
| Legacy Concept Name |
Anti-CS1_Monoclonal_Antibody_HuLuc63 |
|
| Maps_To |
Elotuzumab |
|
| NCI_Drug_Dictionary_ID |
532249 |
|
| PDQ_Closed_Trial_Search_ID |
532249 |
|
| PDQ_Open_Trial_Search_ID |
532249 |
|
| Preferred_Name |
Elotuzumab |
|
| prefixIRI |
NCIT:C66982 |
|
| prefLabel |
Elotuzumab |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor |
|
| UMLS_CUI |
C1832049 |
|
| subClassOf |